Decheng Capital LLC Acquires 5,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Decheng Capital LLC lifted its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 7.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 76,772 shares of the company's stock after buying an additional 5,000 shares during the period. Krystal Biotech makes up approximately 2.6% of Decheng Capital LLC's portfolio, making the stock its 7th largest position. Decheng Capital LLC owned about 0.27% of Krystal Biotech worth $12,027,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in KRYS. Wilmington Savings Fund Society FSB acquired a new stake in Krystal Biotech in the 3rd quarter valued at approximately $40,000. Covestor Ltd increased its holdings in Krystal Biotech by 972.7% in the 4th quarter. Covestor Ltd now owns 708 shares of the company's stock valued at $111,000 after purchasing an additional 642 shares during the last quarter. Avanza Fonder AB purchased a new position in Krystal Biotech in the 4th quarter valued at approximately $119,000. KBC Group NV grew its stake in shares of Krystal Biotech by 46.3% in the fourth quarter. KBC Group NV now owns 939 shares of the company's stock worth $147,000 after acquiring an additional 297 shares in the last quarter. Finally, Blue Trust Inc. increased its position in shares of Krystal Biotech by 74.4% during the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock worth $159,000 after acquiring an additional 433 shares during the period. Institutional investors and hedge funds own 86.29% of the company's stock.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on KRYS shares. Citigroup upped their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. HC Wainwright increased their price target on Krystal Biotech from $221.00 to $240.00 and gave the company a "buy" rating in a research report on Monday. Chardan Capital increased their price target on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. Jefferies Financial Group initiated coverage on Krystal Biotech in a research report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $222.71.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS traded down $5.11 during midday trading on Thursday, hitting $164.77. 127,504 shares of the company's stock were exchanged, compared to its average volume of 295,138. Krystal Biotech, Inc. has a twelve month low of $141.72 and a twelve month high of $219.34. The company has a market cap of $4.76 billion, a PE ratio of 55.11 and a beta of 0.75. The firm's fifty day simple moving average is $175.64 and its 200-day simple moving average is $171.48.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm's quarterly revenue was up 116.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.30 EPS. Equities analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).